Azeliragon

Azeliragon (TTP488 or PF-04494700) is a small-molecule RAGE inhibitor. It is developed by vTv Therapeutics for various cancers, including triple-negative breast cancer, pancreatic cancer.

The chemical reached Phase III trials in slowing cognitive deterioration in early stage Alzheimer's disease patients. It was also tested in people with diabetic neuropathy and animal models of graft-vs-host disease.